Cellectar Biosciences (Warrant)
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CLRBZ and buy or sell other stocks, ETFs, and their options commission-free!About CLRBZ
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
CEOJames V. Caruso
CEOJames V. Caruso
Employees—
Employees—
HeadquartersFlorham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded1996
Founded1996
Employees—
Employees—
CLRBZ Key Statistics
Market cap—
Market cap—
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high—
52 Week high—
52 Week low—
52 Week low—
CLRBZ News
Investing.com 3h
Cellectar reports trial data for cancer drug in rare disease - Investing.com...
TipRanks 3h
Cellectar Biosciences presents efficacy data from CLOVER WaM trialCellectar Biosciences (CLRB) announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inh...